Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

YOU WONT BELIEVE: Adaptimmune therapeutics s return on capital employed insights | Mind Blowing Facts

Benzinga Pro data, Adaptimmune Therapeutics (NASDAQ:ADAP) reported Q1 sales of $3.58 million. Earnings fell to a loss of $50.27 million, resulting in a 29.36% decrease from last quarter. In Q4, Adaptimmune Therapeutics brought in $1.42 million in sales but lost $38.86 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.